Now Reading
$60 million for a world where infections can be cured again: Dr. Marianne Holm leads the renewed commitment to accelerator that helps bring new antibiotics, diagnostics, and vaccines to life
Dark Light

$60 million for a world where infections can be cured again: Dr. Marianne Holm leads the renewed commitment to accelerator that helps bring new antibiotics, diagnostics, and vaccines to life

Marianne Holm has spent her career on a problem most people never think about until it reaches someone they love: an infection that should have cleared up quickly but no longer responds to the medicine meant to cure it.

She is a Danish physician and epidemiologist. Long before she helped direct philanthropy at a global scale, she was working with hospital laboratories across Asia so they could recognize and track resistant bacteria.

Today, as vice president of infectious diseases at the Novo Nordisk Foundation, she is helping put new resources behind one of the most hopeful efforts in modern medicine: a renewed $60 million, four-year commitment to CARB-X, the Boston-based accelerator that helps bring new antibiotics, diagnostics, and vaccines to life.

The new gift builds on the foundation’s first $25 million grant to CARB-X and more than doubles it.

 That reflects real confidence in what the partnership has already achieved. Holm sits on the CARB-X Joint Oversight Board, so she has seen up close how the accelerator turns bright ideas into real progress.

Its approach is personal and practical.

Along with grant funding, it gives small biotech companies and university spinouts the scientific and technical guidance they need to get through the hardest early stage of development.

The results speak for themselves. Projects CARB-X supports are five times more likely to reach clinical development than comparable projects without its help. Of the more than 120 projects it has supported in 15 countries, 29 have already entered or completed clinical trials.

“Addressing antimicrobial resistance requires ambition, expertise, and sustained collaboration across sectors and borders,” Holm said. “CARB-X brings these strengths together in a proven model that helps promising innovations advance further and faster.” For her, expanding the foundation’s support was “a natural next step.”

Her path to that conviction has been both global and grounded. She earned her medical degree at the University of Copenhagen and later studied epidemiology at the London School of Hygiene & Tropical Medicine.

She spent four years at the University of Hong Kong’s School of Public Health, then moved to the International Vaccine Institute in Seoul.

There she led epidemiology and public health research and coordinated large programs that helped countries across Asia build stronger systems for tracking antimicrobial resistance.

The work had her side by side with governments, physicians, and laboratory teams, the people who see first how much is at stake.

She brought that experience to the Novo Nordisk Foundation in 2022, and it guides her work there today.

She sees the challenge clearly. Bacterial infections are the world’s second leading cause of death, and drug resistance makes many of them harder to treat.

Without new solutions, resistance could claim 39 million lives between 2025 and 2050. Holm meets that reality with optimism that is earned rather than naive.

She has argued that progress will come from moving on many fronts together: new antibiotics, vaccines, and diagnostics, along with smarter policy, fair access, and fresh thinking about how to finance discovery.

She also believes in collaboration.

She has helped champion a new consortium with the Gates Foundation and Wellcome in which researchers openly share data in the search for new antibiotics.

The opportunity is extraordinary.

A steady supply of new antibiotics against some of the toughest bacteria, including E. coli and Klebsiella pneumoniae, could save an estimated 11.1 million lives by 2050.

It could also cut health care costs by $84 billion and add $740 billion a year to the global economy.

Better vaccines and faster diagnostics would help even more by preventing infections before they start and getting patients the right treatment sooner.

Kevin Outterson, the Boston University law professor who leads CARB-X, called the renewal “a powerful endorsement of the impact that collaboration can achieve.”

He said it will help the accelerator keep finding the most promising innovations “from anywhere in the world.”

Every product CARB-X supports must include a plan for responsible use and access in low- and middle-income countries, where Holm did much of her early work.

That commitment carries special meaning for her.

The physician who once helped laboratories across Asia read the warning signs is now helping make sure the next generation of cures reaches the communities that need them most.

Her work points toward a future where routine surgery stays safe, childbirth carries less risk, and a simple infection can once again be cured.


© 2026 Lifestyles Magazine International. All Rights Reserved.